References
- Oliveira SB, Monteiro IM. Diagnosis and management of inflammatory bowel disease in children. BMJ [Internet]. 2017 May 31 [cited 2018 Feb 2];357:j2083. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28566467
- Ashton JJ, Borca F, Mossotto E, et al. Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood. Aliment Pharmacol Ther. 2019;49:398–407.
- Lo B, Vester-Andersen MK, Vind I, et al. Changes in disease behaviour and location in patients with crohn’s disease after seven years of follow-up: a Danish population-based inception cohort. J Crohn’s Colitis [Internet]. 2018 Feb 28 [cited 2019 Jun 28];12(3):265–272. Available from: https://academic.oup.com/ecco-jcc/article/12/3/265/4411003
- Ashton JJ, Mossotto E, Ennis S, et al. Personalising medicine in inflammatory bowel disease—current and future perspectives. Transl Pediatr [Internet]. 2019 Jan [cited 2019 Jun 27];8(1):56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30881899
- Fiocchi C. Inflammatory bowel disease: complexity and variability need integration. Front Med [Internet]. 2018 cited 2019 Oct 16;5:75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29619371
- Pigneur B, Seksik P, Viola S, et al. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis [Internet]. 2010 Jun [cited 2019 Jul 10];16(6):953–961. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19834970
- Zeitz J, Fournier N, Labenz C, et al. Risk factors for the development of fistulae and stenoses in Crohn disease patients in the swiss inflammatory bowel disease cohort. Inflamm Intest Dis. 2017;1(4):172–181. doi: 10.1159/000458144.
- Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol [Internet]. 2016 Jan 7 cited 2018 Aug 3;7(1):e135. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26741065
- Olén O, Askling J, Sachs MC, et al. Increased mortality of patients with childhood-onset inflammatory bowel diseases, compared with the general population. Gastroenterology [Internet]. 2019 cited 2019 Jul 11;156(3):614–622. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30342031
- Civitelli F, Nuti F, Oliva S, et al. Looking beyond mucosal healing: effect of biologic therapy on transmural healing in pediatric Crohn’s disease. Inflamm Bowel Dis [Internet]. 2016;22(10):2418–2424. Available from: https://insights.ovid.com/pubmed?pmid=27598739
- Dave M, Loftus EV. Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol [Internet]. 2012;8(1):29–38. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277196/pdf/GH-08-29.pdf
- De Vries LCS, Wildenberg ME, De Jonge WJ, et al. The future of Janus Kinase inhibitors in inflammatory bowel disease. J Crohn’s Colitis [Internet]. 2017 Jul 1 cited 2019 May 31;11(7):885–893. Available from: https://academic.oup.com/ecco-jcc/article/11/7/885/2966915
- Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med [Internet]. 2016 Nov 17 [cited 2018 Feb 23];375(20):1946–1960. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1602773
- Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med [Internet]. 2013;369(8):699–710. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23964932
- Krauthammer A, Tzivinikos C, Assa A, et al. Long-term outcomes of paediatric patients admitted with acute severe colitis - a multicenter study from the paediatric IBD porto group of ESPGHAN. J Crohns Colitis [Internet]. 2019 May 23 cited 2019 Jul 24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31120524
- Akintimehin AO, O’Neill RS, Ring C, et al. Outcomes of a national cohort of children with acute severe ulcerative colitis. Front Pediatr [Internet]. 2018 cited 2019 Jul 24;6:48. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29568735
- Kim HJ, Oh SH, Kim DY, et al. Clinical characteristics and long-term outcomes of paediatric Crohn’s disease: a single-centre experience. J Crohns Colitis. 2017;11:157–164.
- Freeman HJ, Mdcm F. Long-term prognosis of early-onset Crohn ’ s disease diagnosed in childhood or adolescence. 2004;18(11):661–665.
- Walters TD, Kim M-O, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn’s disease. Gastroenterology [Internet]. 2014 Feb [cited 2018 Aug 22];146(2):383–391. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24162032
- Hyams JS, Thomas SD, Gotman N, et al. Clinical and biological predictors of response to standardised paediatric colitis therapy: a multicentre inception cohort study. Lancet. 2019;393(10182):1708–1720.
- Aloi M, Birimberg-Schwartz L, Buderus S, et al. Treatment options and outcomes of pediatric IBDU compared with other IBD subtypes: a retrospective multicenter study from the IBD porto group of ESPGHAN. Inflamm Bowel Dis [Internet]. 2016 cited 2019 Jul 11;22(6):1378–1383. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27135479
- Benchimol EI, Mack DR, Nguyen GC, et al. Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease. Gastroenterology [Internet]. 2014 Oct [cited 2019 Jul 11];147(4):803–813.e7; quiz e14-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24951840
- Oliva-Hemker M, Hutfless S, Al Kazzi ES, et al. Clinical presentation and five-year therapeutic management of very early-onset inflammatory bowel disease in a large North American cohort. J Pediatr [Internet]. 2015 Sep [cited 2019 Jul 11];167(3):527–32.e1-3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25982142
- Jakobsen C, Bartek J, Wewer V, et al. Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease–a population-based study. Aliment Pharmacol Ther [Internet]. 2011 Nov [cited 2019 Jul 11];34(10):1217–1224. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21981762
- Coughlan A, Wylde R, Lafferty L, et al. A rising incidence and poorer male outcomes characterise early onset paediatric inflammatory bowel disease. Aliment Pharmacol Ther [Internet]. 2017 Jun [cited 2018 Oct 19];45(12):1534–1541. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28449214
- Cosnes J, Bourrier A, Nion-Larmurier I, et al. Factors affecting outcomes in Crohn’s disease over 15 years. Gut. 2012;61:1140–1145.
- Peyrin-Biroulet L, Salleron J, Filippi J, et al. Anti-TNF monotherapy for Crohn’s disease: a 13-year multicentre experience. J Crohns Colitis [Internet]. 2016 May [cited 2019 Jul 11];10(5):516–524. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26802084
- Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol [Internet]. 2009 cited 2019 Jul 10;44(4):431–440. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19101844
- Larsen MD, Qvist N, Nielsen J, et al. Use of anti-TNFα agents and time to first-time surgery in paediatric patients with ulcerative colitis and Crohn’s disease anti-TNF α agents and surgery in paediatric IBD patients. 2016 [cited 2018 Oct 19]. Available from: https://academic.oup.com/ecco-jcc/article-abstract/10/6/650/2605115
- Murthy SK, Begum J, Benchimol EI, et al. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut [Internet]. 2019 Jun 12 cited 2019 Jun 28;gutjnl-2019-318440. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31196874
- González-Lama Y, Suárez C, González-Partida I, et al. Timing of thiopurine or anti-TNF initiation is associated with the risk of major abdominal surgery in Crohn’s disease: a retrospective cohort study. J Crohn’s Colitis [Internet]. 2016 Jan [cited 2018 Aug 15];10(1):55–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26520164
- Moran GW, Dubeau M, Kaplan GG, et al. Phenotypic features of Crohn’s disease associated with failure of medical treatment. Clin Gastroenterol Hepatol [Internet]. 2014 Mar [cited 2018 Aug 15];12(3):434–442.e1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23978351
- Ahmad A, Laverty AA, Alexakis C, et al. Changing nationwide trends in endoscopic, medical and surgical admissions for inflammatory bowel disease: 2003-2013. BMJ Open Gastroenterol [Internet]. 2018 cited 2019 Jul 16;5(1):e000191. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29607052
- Debruyn JCC, Soon IS, Hubbard J, et al. Nationwide temporal trends in incidence of hospitalization and surgical intestinal resection in pediatric inflammatory bowel diseases in the United States from 1997 to 2009. Inflamm Bowel Dis [Internet]. 2013 Oct [cited 2019 Jul 16];19(11):2423–2432. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23974991
- Ashton JJ, Versteegh HP, Batra A, et al. Colectomy in pediatric ulcerative colitis: A single center experience of indications, outcomes, and complications. J Pediatr Surg. 2016;51(2):277–281.
- Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn’s disease: a population-based cohort study. Gastroenterology [Internet]. 2008;135(4):1106–1113. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18692056
- Jung YS, Han M, Kim WH, et al. Incidence and clinical outcomes of inflammatory bowel disease in South Korea, 2011-2014: a nationwide population-based study. Dig Dis Sci [Internet]. 2017 [cited 2019 Jul 11];62(8):2102–2112. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28593437
- Lee HS, Park SH, Yang SK, et al. Long-term prognosis of ulcerative colitis and its temporal change between 1977 and 2013: A hospital-based cohort study from Korea. J Crohn’s Colitis. 2015;9:147–155.
- Ganz ML, Sugarman R, Wang R, et al. The economic and health-related impact of Crohn’s disease in the United States: evidence from a nationally representative survey. Inflamm Bowel Dis. 2016;22:1032–1041.
- Zhao M, Lo BZS, Vester-Andersen MK, et al. A 10-year follow-up study of the natural history of perianal Crohn’s disease in a danish population-based inception cohort. Inflamm Bowel Dis. 2019;25(7):1227–1236. doi: 10.1093/ibd/izy374.
- Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis [Internet]. 2002 Jul [cited 2019 Apr 16];8(4):244–250. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12131607
- Rieder F, Zimmermann EM, Remzi FH, et al. Crohn’s disease complicated by strictures: A systematic review. Gut. 2013;62:1072–1084.
- Verstockt B, Cleynen I. Genetic influences on the development of fibrosis in Crohn’s disease. Front Med [Internet]. 2016 May 30 [cited 2019 Apr 15];3:24. Available from: http://journal.frontiersin.org/Article/10.3389/fmed.2016.00024/abstract
- Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology [Internet]. 2010 Oct [cited 2019 Jul 16];139(4):1147–1155. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20637205
- D’Haens G, Rieder F, Feagan BG, et al. Challenges in the pathophysiology, diagnosis and management of intestinal fibrosis in inflammatory bowel disease. Gastroenterology [Internet]. 2019 Jun cited 2019 Jul 16. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0016508519410354
- Lenti MV, Di Sabatino A. Intestinal fibrosis. Mol Aspects Med. 2019;65:100–109. doi: 10.1016/j.mam.2018.10.003.
- Ashton JJ, Beattie RM. Letter: anti-TNF therapy and intestinal resections in Crohn’s disease-are we just delaying the inevitable? Aliment Pharmacol Ther. 2019 Oct;50(7):842–843.
- Louis E, Collard A, Oger AF, et al. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut [Internet]. 2001;49(6):777–782. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11709511
- Scharl M, Rogler G. Pathophysiology of fistula formation in Crohn’s disease. World J Gastrointest Pathophysiol. 2014;5(3):205–212. doi: 10.4291/wjgp.v5.i3.205.
- Karmiris K, Avgerinos A, Tavernaraki A, et al. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease. J Crohn’s Colitis. 2016;10:429–436.
- Isene R, Bernklev T, Høie O, et al. Extraintestinal manifestations in Crohn’s disease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scand J Gastroenterol [Internet]. 2015 Mar [cited 2019 Jul 16];50(3):300–305. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25535653
- Olén O, Askling J, Sachs MC, et al. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014. BMJ [Internet]. 2017 Sep 20 [cited 2018 Feb 2];358:j3951. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28931512
- Nielsen NM, Simonsen J, Frisch M, et al. Decreasing Risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143(2):375-81.e1; quiz e13-4. doi: 10.1053/j.gastro.2012.04.016.
- Söderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009;136(5):1561–1567.
- Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130:1030–1038.
- Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther [Internet]. 2006 Apr 15 cited 2019 Jul 10;23(8):1097–1104. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16611269
- Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. J Am Med Assoc. 2017;318:1679.
- Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology [Internet]. 2017;152:1901–1914.e3. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28193515
- Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36–41.e1.
- Romeo AC, Ventimiglia M, Dipasquale V, et al. Effectiveness and safety of biologics in pediatric inflammatory boweldisease: real-life data from the Sicilian network. Clin Res Hepatol Gastroenterol [Internet]. 2019 Jun 13 cited 2019 Jul 24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31204314
- Dayan JR, Dolinger M, Benkov K, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. J Pediatr Gastroenterol Nutr [Internet]. 2019 Jul [cited 2019 Jul 24];69(1):61–67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31058718
- Naviglio S, Lacorte D, Lucafò M, et al. Causes of treatment failure in children with inflammatory bowel disease treated with infliximab: a pharmacokinetic study. J Pediatr Gastroenterol Nutr [Internet]. 2019 Jan [cited 2019 Jul 24];68(1):37–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30211845
- Alvisi P, Arrigo S, Cucchiara S, et al. Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian society of pediatric gastroenterology, hepatology, and nutrition experience. Biologics [Internet]. 2019 cited 2019 Jul 24;13:13–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30655661
- Ledder O, Assa A, Levine A, et al. Vedolizumab in paediatric inflammatory bowel disease: a retrospective multi-centre experience from the paediatric IBD porto group of ESPGHAN. J Crohns Colitis [Internet]. 2017 cited 2019 Jul 24;11(10):1230–1237. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28605483
- Turner D, Doveh E, Cohen A, et al. Efficacy of oral methotrexate in paediatric Crohn’s disease: a multicentre propensity score study. Gut [Internet]. 2015 Dec [cited 2019 Jul 24];64(12):1898–1904. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25416066
- Zeisler B, Lerer T, Markowitz J, et al. Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013;56:12–18.
- Hyams JS, Lerer T, Mack D, et al. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol [Internet]. 2011;106(5):981–987. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21224840
- Boyle B, MacKner L, Ross C, et al. A single-center experience with methotrexate after thiopurine therapy in pediatric crohn disease. J Pediatr Gastroenterol Nutr. 2010;51(6):714–717.
- Weiss B, Lerner A, Shapiro R, et al. Methotrexate treatment in pediatric crohn disease patients intolerant or resistant to purine analogues. J Pediatr Gastroenterol Nutr. 2009;48:526–530.
- Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology [Internet]. 2000 Oct [cited 2019 Jul 24];119(4):895–902. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11040176
- Waljee AK, Wiitala WL, Govani S, et al. Corticosteroid use and complications in a US inflammatory bowel disease cohort. PLoS One. 2016;11:e0158017.
- Sarlos P, Szemes K, Hegyi P, et al. Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease: a meta-analysis. J Crohns Colitis [Internet]. 2018 Mar 28 [cited 2019 Jul 16];12(4):489–498. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29220427
- Ashton JJ, Batra A, Beattie RM. Paediatric inflammatory bowel disease- brief update on current practice. Paediatr Child Health (Oxford) [Internet]. 2018 Sep [cited 2018 Oct 12];28:507–514. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1751722218301665
- Ashton JJ, Gavin J, Beattie RM. Exclusive enteral nutrition in Crohn’s disease: evidence and practicalities. Clin Nutr. 2019;38(1):80–89. doi: 10.1016/j.clnu.2018.01.020.
- Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol [Internet]. 2005;100(6):1345–1353. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15929768
- Moum B. Which are the 5-ASA compound side effects and how is it possible to avoid them? Inflamm Bowel Dis [Internet]. 2008 Oct [cited 2019 Jul 16];14(Suppl 2):S212–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18816767
- Heap GA, So K, Weedon M, et al. Clinical features and HLA Association of 5-Aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease. J Crohn’s Colitis [Internet]. 2016 Feb [cited 2018 Oct 2];10(2):149–158. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26619893
- Warner B, Johnston E, Arenas-Hernandez M, et al. A practical guide to thiopurine prescribing and monitoring in IBD. Frontline Gastroenterol. [cited 2018 Aug 3];9:10–15. Available from: http://fg.bmj.com/
- Gordon J, Ramaswami A, Beuttler M, et al. EBV status and thiopurine use in pediatric IBD. J Pediatr Gastroenterol Nutr [Internet]. 2016 May [cited 2018 Feb 20];62(5):711–714. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26655944
- Shivaji UN, Sharratt CL, Thomas T, et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49:664–680.
- Papp KA, Griffiths CEM, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168:844–854.
- Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther [Internet]. 2011 May [cited 2019 Jul 16];33(9):987–995. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21366636
- Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76:1253–1262.
- Shim HH, Chan PW, Chuah SW, et al. A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases. JGH Open. 2018;2:223–234.
- Bryant RV, Sandborn WJ, Travis SP. Introducing vedolizumab to clinical practice: who, when, and how? J Crohns Colitis [Internet]. 2015;9(4):356–366. Available from: https://watermark.silverchair.com/api/watermark?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAhwwggIYBgkqhkiG9w0BBwagggIJMIICBQIBADCCAf4GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMFob4U_sivSLgG_P8AgEQgIIBz3gUTUVnAnnry5QF5R6gIt314O64bB1WULwSjtsGH0V16
- Sazonovs A, Kennedy N, Moutsianas L, et al. HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapy. bioRxiv [Internet]. 2018 Sep 9 cited 2018 Nov 12;410035. Available from: https://www.biorxiv.org/content/early/2018/09/09/410035
- Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol [Internet]. 1997 Dec [cited 2018 Oct 2];92(12 Suppl):5S–11S. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9395346
- Zhang Y-Z, Li -Y-Y. Inflammatory bowel disease: pathogenesis. World J Gastroenterol [Internet]. 2014 Jan 7 cited 2018 Oct 2;20(1):91–99. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24415861
- Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology [Internet]. 2014;146(6):1489–1499. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24560869
- Peloquin JM, Goel G, Villablanca EJ, et al. Mechanisms of pediatric inflammatory bowel disease. Annu Rev Immunol [Internet]. 2016 May 20 cited 2018 Oct 2;34(1):31–64. Available from: http://www.annualreviews.org/doi/10.1146/annurev-immunol-032414-112151
- Hendy P, Hart A, Irving P. Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide. cited 2018 Aug 3. Available from: http://fg.bmj.com/
- Lim SZ, Chua EW. Revisiting the role of thiopurines in inflammatory bowel disease through pharmacogenomics and use of novel methods for therapeutic drug monitoring. Front Pharmacol. 2018;9:1107.
- Coelho T, Andreoletti G, Ashton JJ, et al. Genes implicated in thiopurine-induced toxicity: comparing TPMT enzyme activity with clinical phenotype and exome data in a paediatric IBD cohort. Sci Rep. 2016;6:34658.
- Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet [Internet]. 2014 Oct 14 [cited 2018 Oct 2];46(10):1131–1134. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25217962
- Lenti MV, Selinger CP. Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions. Expert Rev Gastroenterol Hepatol [Internet]. 2017 Mar [cited 2019 Oct 16];11(3):215–226. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28099821
- Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis [Internet]. 2014;8(10):1179–1207. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24909831
- Weiser M, Simon JM, Kochar B, et al. Molecular classification of Crohn’s disease reveals two clinically relevant subtypes. Gut [Internet]. 2016; Available from: https://www.ncbi.nlm.nih.gov/pubmed/27742763
- Denson LA, Jurickova I, Karns R, et al. Clinical and genomic correlates of neutrophil reactive oxygen species production in pediatric patients with Crohn’s disease. Gastroenterology [Internet]. 2018 Jun 1 [cited 2018 Nov 6];154(8):2097–2110. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29454792
- Kolho K-L, Korpela K, Jaakkola T, et al. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol [Internet]. 2015 Jun 19 [cited 2018 Dec 17];110(6):921–930. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25986361
- Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study. Lancet [Internet]. 2017 Apr 29 [cited 2018 Aug 9];389(10080):1710–1718. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28259484
- Marigorta UM, Denson LA, Hyams JS, et al. Transcriptional risk scores link GWAS to eQTLs and predict complications in Crohn’s disease. Nat Genet [Internet]. 2017 Aug 14 [cited 2018 Aug 9];49(10):1517–1521. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28805827
- Ziv-Baran T, Hussey S, Sladek M, et al. Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn’s disease. Aliment Pharmacol Ther [Internet]. 2018 Nov 18 cited 2018 Nov 20;48:1242–1250.
- Dulai PS, Boland BS, Singh S, et al. Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn’s disease. Gastroenterology [Internet]. 2018 cited 2019 Oct 16;155(3):687–695.e10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29857091
- Lee JC, Lyons PA, McKinney EF, et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest [Internet]. 2011 Oct 3 [cited 2018 Aug 9];121(10):4170–4179. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21946256
- Arijs I, Quintens R, Van Lommel L, et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohnʼs disease‡. Inflamm Bowel Dis [Internet]. 2010 Dec [cited 2018 Aug 9];16(12):2090–2098. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20848504
- Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut [Internet]. 2009 Dec 1 [cited 2018 Aug 9];58(12):1612–1619. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19700435
- Gaujoux R, Starosvetsky E, Maimon N, et al. Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD. Gut [Internet]. 2019 cited 2019 Oct 16;68(4):604–614. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29618496
- Douglas GM, Hansen R, Jones CMA, et al. Multi-omics differentially classify disease state and treatment outcome in pediatric Crohn’s disease. Microbiome [Internet]. 2018 Dec 15 [cited 2018 Feb 6];6(1):13. Available from: https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0398-3
- West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23:579–589.
- Hrdinka M, Schlicher L, Dai B, et al. Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling. Embo J [Internet]. 2018 Sep 3 [cited 2019 Jun 13];37(17):e99372. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30026309